Insulin aspart
aspart, Asp(B28) human insulin, faster-acting insulin aspart, insulin aspart-szjj, B28-aspartic acid human insulin
Insulin aspart is a rapid-acting recombinant insulin analogue in which a single proline residue is replaced by aspartic acid, introducing a negative charge that stops the molecule clustering into slowly absorbed hexamers. It covers mealtime glucose rises and is widely used in pumps. It is the only rapid-acting analogue with a dedicated randomised trial in pregnancy.
Mechanism
Insulin aspart is human insulin with proline at position B28 replaced by aspartic acid. Proline B28 lies at the interface between insulin monomers within the dimer, and its removal in favour of a negatively charged residue creates electrostatic repulsion between the two monomer surfaces. As with lispro, the design intent is not to change receptor pharmacology at all but to destabilise the self-association that slows absorption. Zinc-stabilised hexamers still form in the formulation, so the product is stable in the vial and cartridge, but on injection and dilution into interstitial fluid the hexamers dissociate rapidly into dimers and monomers, which are the only species that cross the capillary endothelium efficiently.
The result is appearance in plasma within about 10 to 20 minutes, a peak effect at one to three hours, and a duration of three to five hours, compared with roughly double those times for soluble human insulin. Insulin receptor affinity, IGF-1 receptor affinity and metabolic-to-mitogenic potency ratio are all close to those of human insulin, and downstream signalling (receptor autophosphorylation, IRS-1/2 recruitment, PI3K-AKT activation, GLUT4 translocation into muscle and adipocyte membranes, suppression of hepatic gluconeogenesis and glycogenolysis, inhibition of lipolysis and stimulation of protein synthesis) is indistinguishable. A 'faster-acting' formulation of the same peptide adds niacinamide, which increases the proportion of monomers available immediately after injection, and L-arginine as a stabiliser, bringing onset forward by roughly five minutes and increasing early exposure.
What the research shows
The registration evidence for aspart is solid and internally consistent. The 1,070-participant European trial found a small HbA1c advantage over regular human insulin alongside clearly lower postprandial glucose and better patient-reported satisfaction, and the double-blind crossover trial by Heller and colleagues located the hypoglycaemia benefit specifically in major nocturnal episodes rather than in overall rates. Pharmacokinetically the case is settled: aspart appears in plasma roughly twice as fast as soluble human insulin and clears roughly twice as fast, which is exactly what a mealtime insulin should do.
The negative and null results matter as much. Cochrane's pooled analysis of the rapid-acting analogue class placed the HbA1c benefit at around 0.15 percentage points with low-certainty evidence and no data on complications, mortality or quality of life, meaning that the cost differential between analogues and regular human insulin rests on a modest surrogate advantage plus convenience, not on demonstrated outcome improvement. The Nørgaard meta-analysis in special populations found the analogues at least as safe as regular insulin in pregnancy and paediatric use but with small effect sizes and a thinner evidence base than in adult type 1 diabetes. Aspart's distinctive position rests less on any superiority over lispro or glulisine (head-to-head differences among the three rapid analogues are negligible) than on its dedicated randomised pregnancy trial and its status as the prandial insulin used in the comparator arms of most modern basal insulin trials, including the degludec and icodec programmes.
Evidence assessment
High-quality evidence
Licensed in the European Union in 1999 and by the FDA in 2000 on the basis of large multicentre randomised controlled trials, including a 1,070-participant European trial and a 322-participant randomised trial in pregnancy, a rarity in this field. Cochrane systematic review evidence confirms the pharmacokinetic and postprandial advantage while rating the clinical benefit over regular human insulin as minor, with no long-term outcome data.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial Preclinical only
Insulin aspart gave a small but statistically significant HbA1c advantage over unmodified human insulin (of the order of 0.1 percentage points), with lower postprandial glucose and improved treatment satisfaction. This was the principal European registration trial.
Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes Preclinical only
Overall hypoglycaemia rates were comparable between aspart and soluble human insulin, but major nocturnal hypoglycaemic episodes were significantly less frequent with aspart. This is the key hypoglycaemia dataset for aspart and is more nuanced than promotional summaries suggest: the benefit is specifically nocturnal, not across the board.
Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women Preclinical only
Insulin aspart was at least as safe and effective as regular human insulin in pregnancy, with comparable glycaemic control and numerically fewer major hypoglycaemic episodes. Rapid-acting analogues rarely have dedicated randomised pregnancy data; this trial is the reason aspart has an explicit pregnancy position in guidelines.
Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus Preclinical only
Only a minor benefit of short-acting analogues over regular human insulin, with HbA1c differences of the order of 0.15 percentage points and low certainty of evidence. No data at all on long-term complications, mortality or quality of life. An important corrective to individual registration trials.
Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis Preclinical only
Rapid-acting analogues including aspart were at least as effective and safe as regular human insulin in these populations, with small effect sizes and an evidence base thinner than in general adult type 1 diabetes.
Safety
Hypoglycaemia is the dose-limiting adverse effect and occurs earlier after injection than with regular human insulin, so mistiming relative to a meal is a frequent precipitant. Because the duration is short and no subcutaneous depot persists, interruption of pump delivery can produce diabetic ketoacidosis within a few hours. Weight gain, hypokalaemia (insulin drives potassium intracellularly), injection-site lipohypertrophy from poor site rotation and local injection reactions are common. Less common effects include systemic insulin allergy, lipoatrophy, peripheral oedema, transient refractive changes when glucose falls rapidly, and anti-insulin antibody formation. Renal and hepatic impairment reduce insulin clearance and increase hypoglycaemia risk. Concurrent thiazolidinedione use increases fluid retention and heart-failure risk. Recurrent hypoglycaemia blunts counter-regulatory warning symptoms, producing hypoglycaemia unawareness, which carries specific driving implications; UK drivers on insulin must comply with DVLA rules. Insulin is designated a high-alert medicine, and confusion between rapid-acting and long-acting products or between concentrations is a documented cause of serious harm. Non-medical use for supposed anabolic effect has caused deaths and permanent hypoglycaemic brain injury; there is no safe recreational or performance-enhancing use of any insulin.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed by the MHRA for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above (formulation-dependent). Prescription-only medicine (POM). Recommended within NICE guidance NG17 for type 1 diabetes and NG3 for diabetes in pregnancy, and included on the WHO Model List of Essential Medicines as a rapid-acting insulin. |
| United States | FDA-approved in June 2000 for adults and children with diabetes mellitus for the control of hyperglycaemia. A faster-acting formulation containing niacinamide and L-arginine was approved in September 2017. Insulin aspart has been regulated as a biological product since March 2020, and a biosimilar insulin aspart has since been licensed. Prescription-only. |
| WADA (sport) | Prohibited at all times, in and out of competition, under section S4 of the WADA Prohibited List covering insulins and insulin-mimetics. A Therapeutic Use Exemption is required for athletes with diabetes. |
Questions
Proline at B28 sits at the contact surface between two insulin monomers in the dimer. Replacing it with aspartic acid puts a negative charge at that interface, so the two surfaces repel each other. Zinc hexamers still assemble in the vial, but they break apart much faster once injected and diluted, and only monomers and dimers can cross the capillary wall into the bloodstream.
Not meaningfully. Head-to-head comparisons of aspart, lispro and glulisine show essentially interchangeable pharmacokinetics and clinical outcomes. Choice usually comes down to device preference, formulary position and cost rather than any pharmacological difference. Aspart has the distinction of a dedicated randomised trial in pregnancy, which the others lack.
A 322-participant randomised trial in pregnant women with type 1 diabetes found insulin aspart at least as safe and effective as regular human insulin. That trial is why aspart has an explicit place in pregnancy guidance including NICE NG3. Insulin requirements change substantially through pregnancy and management is a matter for a specialist antenatal diabetes team.
It is the same aspart peptide in a different formulation. Niacinamide increases the fraction of insulin present as monomers immediately after injection, and L-arginine acts as a stabiliser. Onset moves forward by around five minutes with greater early insulin exposure. The change is to the excipients, not the molecule.
No trial has shown that it does, relative to regular human insulin. Cochrane reviewers found no data on complications, mortality or quality of life for any rapid-acting analogue. The complication reductions established by the DCCT were achieved using regular human insulin and isophane insulin; what the analogues add is faster kinetics, more flexible meal timing, and less nocturnal hypoglycaemia.